Limbitrol Ds

Depression, Enterocolitis, Anxiety Disorders + 6 more

Treatment

8 FDA approvals

20 Active Studies for Limbitrol Ds

What is Limbitrol Ds

Chlordiazepoxide

The Generic name of this drug

Treatment Summary

Chlordiazepoxide is a medication used to treat anxiety, seizures, and memory loss. It can also be used to help with alcohol withdrawal symptoms.

Librax

is the brand name

image of different drug pills on a surface

Limbitrol Ds Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Librax

Chlordiazepoxide

1966

112

Approved as Treatment by the FDA

Chlordiazepoxide, otherwise known as Librax, is approved by the FDA for 8 uses like Enterocolitis and Irritable Bowel Syndrome .

Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Irritable Bowel Syndrome

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

Irritable Bowel Syndrome (IBS)

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

acute Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Depression

Used to treat Depression in combination with Amitriptyline

Peptic Ulcer Disease

Used to treat Peptic Ulcer Disease in combination with Clidinium

Anxiety

Used to treat moderate to severe anxiety in combination with Amitriptyline

moderate to severe symptoms

Used to treat moderate to severe symptoms in combination with Amitriptyline

Effectiveness

How Limbitrol Ds Affects Patients

Chlordiazepoxide has calming, sleep-inducing, appetite-stimulating, and mild pain-relieving effects. It seems to stop some types of activity in the brain stem. Research has shown that it could affect the limbic system in the brain, which is involved in emotion. In one study, hostile monkeys became calmer after taking chlordiazepoxide. Other studies have found that the drug could reduce fear and aggression in rats that had been made aggressive due to brain damage. The dose of chlordiazepoxide used to reduce aggression was much lower than the dose needed to cause drowsiness.

How Limbitrol Ds works in the body

Chlordiazepoxide works by binding to certain sites in the brain, which allows it to increase the effectiveness of a neurotransmitter called GABA. This induces relaxation and reduces anxiety, as well as providing sedative and muscle-relaxing effects.

When to interrupt dosage

The suggested dosage of Limbitrol Ds is subject to the diagnosed disorder, including Syndrome, moderate to severe symptoms and Depression. The quantity of dosage is contingent upon the method of administration outlined in the table below.

Condition

Dosage

Administration

moderate to severe symptoms

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Enterocolitis

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety Disorders

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Irritable Bowel Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Peptic Ulcer Disease

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Limbitrol Ds.

Common Limbitrol Ds Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.

Ethanol

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methadone

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Chlordiazepoxide is combined with Oliceridine.

Limbitrol Ds Toxicity & Overdose Risk

The lethal dose of this drug in rats is 537mg/kg if taken orally. Overdosing on this drug may cause shallow breathing, muscle weakness, and excessive sleepiness.

image of a doctor in a lab doing drug, clinical research

Limbitrol Ds Novel Uses: Which Conditions Have a Clinical Trial Featuring Limbitrol Ds?

Currently, 794 active clinical trials are examining the potential of Limbitrol Ds in reducing moderate to severe Anxiety Disorders and related Syndromes.

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

53 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Enterocolitis

0 Actively Recruiting

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Peptic Ulcer Disease

0 Actively Recruiting

Anxiety

2 Actively Recruiting

Not Applicable

Anxiety

0 Actively Recruiting

Depression

298 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

moderate to severe symptoms

0 Actively Recruiting

Limbitrol Ds Reviews: What are patients saying about Limbitrol Ds?

5

Patient Review

1/12/2008

Limbitrol Ds for Anxiousness associated with Depression

4

Patient Review

1/16/2010

Limbitrol Ds for Anxiousness associated with Depression

This prescription has allowed me to finally get a good night's sleep. I have Rheumatoid Arthritis, so previously it was difficult for me to even fall asleep due to discomfort. Ambien helped me fall asleep but I would always wake up after a few hours. This medication keeps me asleep for around 7 hours, which is great!

3

Patient Review

3/15/2010

Limbitrol Ds for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

2.3

Patient Review

3/20/2013

Limbitrol Ds for Anxiousness associated with Depression

I felt okay the first week, but then began to experience increased levels of depression and anxiety. These nightmares and thoughts were really terrible, so I stopped taking the medication. I changed my diet and started working out, which made me feel a lot better. A year later and I'm doing things I never thought possible- like rock climbing with friends.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about limbitrol ds

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do they still make Limbitrol?

"The Limbitrol brand name has been discontinued in the U.S. Generic versions of the product have been approved by the FDA and may be available."

Answered by AI

What are the side effects of Limbitrol?

"The following effects may occur: drowsiness, dizziness, dry mouth, blurred vision, constipation, bloating, trouble urinating, and weight gain. If you experience any of these effects, tell your doctor or pharmacist. To reduce the risk of dizziness or fainting, stand up slowly when you get up from a sitting or lying position."

Answered by AI

What is Limbitrol prescribed for?

"The drug LIMBITROL is indicated for the treatment of patients who have moderate to severe depression along with moderate to severe anxiety. The drug tends to work faster and with fewer treatment failures than when either amitriptyline or chlordiazepoxide are used alone."

Answered by AI

Clinical Trials for Limbitrol Ds

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials
Image of Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Mindfulness for Postpartum Anxiety

18+
Female
Hamilton, Canada

Postpartum anxiety (PPA) affects up to 20% of mothers in the first year after delivery, with mothers often reporting both psychological and physical symptoms. Present non-pharmacological interventions are effective at improving some psychological aspects of PPA such as anxiety, depressive mood, and distress. However, current interventions are not effective in improving emotion regulation (ER), something that many with PPA experience impairment in. Current interventions also seldom target the physical aspects of anxiety, such as bodily awareness - sensing and understanding internal signals in the body (e.g., sensing a fast heartbeat). There is a link between ER and bodily awareness, however psychological interventions that target both these aspects have not been investigated in the PPA population. As a result, a mind-body intervention targeting both ER and bodily awareness is needed to offer a more holistic treatment option. The purpose of the proposed study is to test the effectiveness of a 4-week mindfulness intervention on anxiety symptoms, ER, and bodily awareness in those with PPA. We will use self-report questionnaires alongside brain imaging (functional magnetic resonance imaging; fMRI) to evaluate the effectiveness. Combining both subjective and objective measures will provide greater confidence in our findings, ensuring a more comprehensive understanding of the intervention's impact. Self-report questionnaires will be administered at enrolment, immediately post-intervention, and 4 weeks post-intervention. Brain imaging will be conducted at enrolment and immediately post-intervention. We believe this intervention will lead to improvements in anxiety symptoms, ER, and bodily awareness on the questionnaires and fMRI scans. If effective, the proposed mindfulness intervention will target a broader range of psychological and physical symptoms, and reduce the negative impact of PPA on mothers and their infants in Canada and beyond.

Recruiting
Has No Placebo

Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton (+1 Sites)

Sheryl M Green, Ph.D., C.Psych

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials